Uncategorized

The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin. These are the results of a clinical trial part-funded by Cancer Research UK and published in The Lancet Oncology on Tuesday. Around 4,400 patients on the TACT2 clinical trial were treated with the chemotherapy drug epirubicin followed by either capecitabine or CMF, after surgery. Researchers at The Institute of Cancer Research, London, and the Cancer Research UK Edinburgh Centre found that capecitabine resulted in patients experiencing fewer side effects and having a better quality of life, and it was as effective at preventing cancer’s return as CMF.

See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-06-06-new-chemotherapy-approach-offers-breast-cancer-patients-a-better-quality-of-life